Pfizer recall two batches of migraine drug Relpax

pharmafile | August 16, 2019 | News story | Medical Communications |  FDA, Pfizer, Relpax, migraine, pharma, recall 

Pfizer has recalled two lots of its migraine drug Relpax over concerns about microbiological contamination.

In a statement on the FDA website, Pfizer said: “Individuals who consume oral products contaminated with microorganisms are at risk of bacterial dissemination from the gut to the bloodstream potentially resulting in serious, life- threatening infections.”

However the firm said the risk of infection was low for the general population. The risk may be higher for those with compromised immune systems, cystic fibrosis and chronic granulomatous disease.

The two lots of 40mg tablets are labelled AR5407 and CD4565. Pfizer has not yet received any complaints or reports of adverse events relating to the batches.

Louis Goss